These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 10470201)
41. [The significance of TU M2-PK tumor marker for lung cancer diagnostics]. Oremek G; Kukshaĭte R; Sapoutzis N; Ziolkowski P Klin Med (Mosk); 2007; 85(7):56-8. PubMed ID: 17882813 [TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. Pezzilli R; Migliori M; Morselli-Labate AM; Campana D; Ventrucci M; Tomassetti P; Corinaldesi R Anticancer Res; 2003; 23(3C):2969-72. PubMed ID: 12926146 [TBL] [Abstract][Full Text] [Related]
43. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313 [TBL] [Abstract][Full Text] [Related]
44. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312 [TBL] [Abstract][Full Text] [Related]
45. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Schneider J; Schulze G Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971 [TBL] [Abstract][Full Text] [Related]
47. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068 [TBL] [Abstract][Full Text] [Related]
48. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337 [TBL] [Abstract][Full Text] [Related]
50. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675 [TBL] [Abstract][Full Text] [Related]
51. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy. Oremek GM; Rutner F; Sapoutzis N; Sauer-Eppel H Anticancer Res; 2003; 23(2A):1155-8. PubMed ID: 12820364 [TBL] [Abstract][Full Text] [Related]
52. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Kumar Y; Gurusamy K; Pamecha V; Davidson BR Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316 [TBL] [Abstract][Full Text] [Related]
53. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127 [TBL] [Abstract][Full Text] [Related]
55. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758 [TBL] [Abstract][Full Text] [Related]
56. [Clinical significance for detection of circulating cancer cells in renal cell carcinoma]. Uemura H; Hirao Y Gan To Kagaku Ryoho; 2002 Oct; 29(10):1712-8. PubMed ID: 12402419 [TBL] [Abstract][Full Text] [Related]
57. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710 [TBL] [Abstract][Full Text] [Related]